Arturus Therapeutics, Inc. , a leader in RNAi disease treatment technology, today announced that it has raised $1. 3 million in a seed funding round led by multiple high net worth private investors from the United States and Canada.
Arcturus Therapeutics, a San Diego-based company dedicated to the discovery and development of therapeutic modalities, was founded in 2013 to pursue RNA interference (RNAi) solutions for rare diseases for which there is no adequate treatment.
“In recent years, researchers have made great strides in diagnosing, treating and even preventing a variety of rare diseases. Still, much more remains to be done because there are no treatments for the vast majority of rare diseases that affect the estimated 25 million to 30 million Americans,” said Joseph E. Payne, president and chief executive officer, Arcturus “Arcturus is poised to contribute to significant disruptive and promising treatments for rare diseases, to improve the quality of life and to improve society. “That’s right.
Arcturus’ recent round of funding underscores the significant potential of the RNAi market and its role in the development of innovative pharmaceutical therapies. According to a new report from Global Industry Analysts, Inc. The global market for RNA interference (RNAi) is expected to reach $4. EUR 04 billion by 2017
The new round of funding will support the purchase of capital equipment and the further development of Arcturus’ intellectual property of RNAi delivery technologies, as well as the RNAi target selection, design and in vitro proof of concept studies.
Arcturus Therapeutics was founded by Joseph Payne and Pad Chivukula, pharmaceutical scientists and nanoparticle delivery technology experts, who have previously carried out a preclinical development project through IND filing for a novel RNAi therapeutic treatment for fibrosis. The founders of Arcturus have extensive experience in delivering multiple drug products to reputable companies such as DuPont Pharmaceuticals, Merck, Bristol-Myers Squibb, Kalypsys and Nitto Denko.
Arcturus Therapeutics is located in San Diego-based Janssen Labs, where disruptive research is underway by some of today’s leading scientists and emerging technologists who work side by side to develop pioneering medical treatments. Arcturus has recently announced new appointments to its Board of Directors and Scientific Advisory Board.
Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, California. , Arcturus Therapeutics is set to become the industry leader in the application of RNAi technologies for the treatment of diseases and improved quality of life. The company’s aim is to develop cutting-edge technology and novel treatments for rare diseases for which there is no adequate treatment. Supported by a management team with extensive experience in the discovery and development of therapeutic modalities, Arcturus is at the forefront of research and development of siRNA drug delivery systems for nanoparticles. Visit us at The ArtturusRx Com